Skip to content
value.today

Luminary Therapeutics, Inc.

🇺🇸 Minneapolis, Minnesota, USABiotechnologyFounded 2019
Total raised
$10 M
4 rounds on record
Latest round
$1 M
Oct 2025
First round on record
Oct 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Luminary Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$1 MNo. 4Under $2 million

Luminary Therapeutics, Inc.: Raise no. 4, Oct 2025

Investors in this round

6 investors had bought by the notice of Nov 5, 2025: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $12 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff Liter · Executive Officer, Director, Promoter
  • Branden Moriarity · Director
  • James Haymaker · Director, Promoter
  • Jeff Ross · Director
  • John Wells · Director
  • Mark Chance · Director
  • Tracey Lodie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “3(a) and (b) include the conversion of approximately $581,127 in previously issued SAFEs, which will occur when the Company has sold $3,000,000 in shares of Series B-1 Preferred; 13(a) and (c) include the issuance of warrants.”

Signed by Jeff Liter, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 5, 2025. Read the notice at the SEC.

equity, optionsSEC
Nov 2024$5 MNo. 3$2 to $10 million

Luminary Therapeutics, Inc.: Raise no. 3, Nov 2024

Investors in this round

48 investors had bought by the notice of Jan 8, 2025: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff Liter · Executive Officer, Director, Promoter
  • James Haymaker · Director, Promoter
  • Jeff Ross · Director
  • John Wells · Director
  • Mark Chance · Director
  • Tracey Lodie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “13(a) and 13(b) include the conversion of previously issued Simple Agreements for Future Equity (SAFEs).”

Signed by Jeff Liter, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 8, 2025. Read the notice at the SEC.

equitySEC
Sep 2022$2 MNo. 2$2 to $10 million

Luminary Therapeutics, Inc.: Raise no. 2, Sep 2022

Investors in this round

12 investors had bought by the notice of Aug 3, 2023: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: SAFE (Simple Agreement Future Equity)
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff Liter · Executive Officer, Director, Promoter
  • John Hurley · Executive Officer
  • Alexander Naydich · Director
  • David Largaespada · Director, Promoter
  • James Haymaker · Director
  • John Wells · Director
  • Mark Chance · Director
  • Tracey Lodie · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeff Liter, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 3, 2023. Read the notice at the SEC.

equitySEC
Oct 2019$1 MNo. 1Under $2 million

Luminary Therapeutics, Inc.: Raise no. 1, Oct 2019

Investors in this round

11 investors had bought by the notice of Nov 14, 2019: 9 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Largaespada · Executive Officer, Director, Promoter
  • Jeff Liter · Executive Officer, Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeff Liter, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 14, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Luminary Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2025

That is all the official record says: Luminary Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Luminary Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 48 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Luminary Therapeutics, Inc.
NameRoleNamed in
Jeff LiterExecutive officerNov 2025
John HurleyExecutive officerAug 2023
David LargaespadaExecutive officerNov 2019
Branden MoriarityDirectorNov 2025
James HaymakerDirectorNov 2025
Jeff LiterDirectorNov 2025
Jeff RossDirectorNov 2025
John WellsDirectorNov 2025
Mark ChanceDirectorNov 2025
Tracey LodieDirectorNov 2025
Alexander NaydichDirectorAug 2023
David LargaespadaDirectorAug 2023
George CoxDirectorJan 2023
Peter KosaDirectorJan 2023
James HaymakerPromoterNov 2025
Jeff LiterPromoterNov 2025
David LargaespadaPromoterAug 2023